nach oben

Erschienen in:

18.09.2017 | Hodgkin-Lymphom | fortbildung

Vielversprechende Daten

Immuntherapie beim Hodgkin-Lymphom

verfasst von: Dr. med. Ruth Scheuvens

Erschienen in: InFo Hämatologie + Onkologie | Sonderheft 1/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Standardtherapie bei Patienten mit Hodgkin-Lymphom basiert auf Chemo- und Strahlentherapie. Da diese mit Kurz- und Langzeitnebenwirkungen einhergeht, wird intensiv nach alternativen Behandlungsmöglichkeiten mit vergleichbarer Wirksamkeit, aber weniger Nebenwirkungen geforscht. Immuntherapeutische Ansätze haben vielversprechende Ergebnisse erzielt.

Behringer K et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013;31(2):231–9.PubMedCrossRef

Behringer K et al. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. J Clin Oncol. 2016;34(36):4329–37.PubMedCrossRef

Kreissl S et al. Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016;17(10):1453–62.PubMedCrossRef

van Nimwegen FA et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007–17.PubMedCrossRef

Schaapveld M et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma. N Engl J Med. 2015;373(26):2499–511.PubMedCrossRef

Arai S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54(11): 2531–3.PubMedCrossRef

Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2009;9(1):15–27.PubMedCrossRef

Liu Y et al. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol. 2014;24:15–22.PubMedCrossRef

Behringer K et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385(9976):1418–27.PubMedCrossRef

10.

von Tresckow B et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9): 907–13.CrossRef

11.

Borchmann P et al. Treatment reduction in patients with advanced-stage Hodgkin Lymphoma and negative interim PET: final results of the international, randomized Phase 3 trial HD18 by the German Hodgkin Study Group. Haematologica. 2017;102(Suppl 2):Abstr S150.

12.

Borchmann P et al. eBEACOPP with or without Rituximab in Interim-PET-positive advanced-stage Hodgkin-Lymphoma: updated results oft he international, randomized Phase 3 GHSG HD18 trial. Hematol Oncol. 2017;35(Suppl 2):65.CrossRef

13.

Engert A et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.PubMedCrossRef

14.

Schmitz N et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71.PubMedCrossRef

15.

Sasse S et al. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk Lymphoma. 2016;57(5):1067–73.PubMedCrossRef

16.

Engert A. CD30-positive malignant lymphomas: time for a change of management? Haematologica. 2013;98(8):1165–8.CrossRef

17.

Younes A et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9.PubMedPubMedCentralCrossRef

18.

Gopal AK et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–43.PubMedPubMedCentralCrossRef

19.

Younes A et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study; 2013 Dec. Report No.: 1474-5488 (Electronic) 1470-2045 (Linking).

20.

Moskowitz CH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62.PubMedCrossRef

21.

Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.PubMedPubMedCentralCrossRef

22.

Parry RV et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543–53.PubMedPubMedCentralCrossRef

23.

Green MR et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–77.PubMedPubMedCentralCrossRef

24.

Green MR et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–8.PubMedPubMedCentralCrossRef

25.

Roemer MGM et al. Classical Hodgkin Lymphoma with Reduced â2M/MHC Class I Expression is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res. 2016;4(11):910–6.PubMedCrossRef

26.

Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.PubMedCrossRef

27.

Younes A et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–94.PubMedPubMedCentralCrossRef

28.

Timmerman JM et al. Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 2016;128(22): 1110.

29.

Engert A et al. Nivolumab for relapsed/refractory classical hodgkin lymphoma after autologous transplant: full results after extended follow-up of the multicohort multicenter phase 2 checkmate 205 trial. EHA. 2017;Abstr S412.

30.

Engert A et al. Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma. Blood. 2016;128(22):1831.

31.

Armand P, et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016 Jun 27. [Epub ahead of print].

32.

Chen R et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–32.PubMedCrossRef

33.

Borchmann P et al. ASH 2015, Abstract #580

34.

Evens AM et al. The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol. 2013;161(1):76–86.PubMedPubMedCentralCrossRef

35.

Halbsguth TV et al. Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2010;116(12): 2026–32.PubMedCrossRef

Titel: Vielversprechende Daten
Immuntherapie beim Hodgkin-Lymphom
verfasst von: Dr. med. Ruth Scheuvens
Publikationsdatum: 18.09.2017
Verlag: Springer Medizin
Schlagwörter: Hodgkin-Lymphom
Brentuximab vedotin
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe Sonderheft 1/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-017-5791-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Immuntherapie beim Hodgkin-Lymphom

Zusammenfassung

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2017

Status quo und ein Blick in die Zukunft

CME: Management immunvermittelter Nebenwirkungen

Alectinib reduziert das Progressionsrisiko

Immuntherapie von akuten Leukämien: immer mehr Optionen

Zukünftige Entwicklungen in der Immunonkologie

Immuntherapie von Nieren-, Prostatakarzinom & Co.

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie